FDA Cites Adulteration In Warning Letter To Juice Beauty Manufacturer
This article was originally published in The Rose Sheet
Executive Summary
FDA’s latest warning letter to a cosmetics firm departs from the agency’s crackdown on drug-like structure/function claims, targeting contract manufacturer Gemdo Cosmetics for facility conditions and evidence of microbial contamination that cause its products to be adulterated under the Federal Food, Drug and Cosmetic Act. In the April 16 letter, FDA cites eye products produced at the firm’s plant, including Juice Beauty offerings subject to a July 2014 recall.
You may also be interested in...
What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?
Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.
What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?
Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.
What Comes First? FDA Excessive Claims Finding Or Facility Inspection?
Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.